Secondary Logo

Journal Logo

Epidemiology and Social

Risk factors for HIV infection among men who have sex with men

Koblin, Beryl Aa; Husnik, Marla Jb; Colfax, Grantc; Huang, Yijiand; Madison, Mariae; Mayer, Kennethf; Barresi, Patrick Jg; Coates, Thomas Jh; Chesney, Margaret Ai; Buchbinder, Susanc

Author Information
doi: 10.1097/01.aids.0000216374.61442.55
  • Free



In the United States, men who have sex with men (MSM) continue to be the group comprising the largest proportion of new HIV infections [1]. In the early years of the epidemic, the incidence of HIV infection among MSM in the epicenters in the United States peaked at a high of 8 to 10% per year [2] and then fell to below 1% in the late 1980s and early 1990s [3]. Consistently through this time period, the main sexual risk behavior for HIV infection among MSM has been unprotected anal intercourse, with higher risk associated with receptive intercourse in comparison with insertive intercourse [4–15]. In addition to high-risk sexual risk behaviors, studies examining risk factors for HIV incidence have found independent associations with increased number of partners; substance use including amphetamine, nitrite inhalent and cocaine use; and sexually transmitted infections including syphilis, gonorrhea, and herpes simplex virus type 2 [4,8,10–14,16–19]. A recent publication to examine risk factors for HIV infection among MSM recruited in the mid 1990s also found a lack of circumcision significantly associated with HIV acquisition controlling for sexual risk behaviours [18].

From 1999 to 2003, the EXPLORE Study was conducted to test a behavioral intervention in preventing acquisition of HIV infection among MSM in the United States. The purpose of this analysis was to determine risk factors for HIV acquisition in one of largest cohorts of MSM recruited in recent years. The cohort was recruited and followed during a time period of increases in the prevalence of risk behaviors and HIV incidence in MSM communities [3,20–22]. Furthermore, in contrast to behavioral data collected in previous cohorts, the data on risk factors in the EXPLORE Study were collected using computer-assisted self-interviewing technology as a means to minimize under-reporting of risk behaviors.

Materials and methods

This study was carried out in six cities in the United States: Boston, Massachusetts; Chicago, Illinois; Denver, Colorado; New York, New York; San Francisco, California; and Seattle, Washington. Details regarding the methods and results of the randomized trial have been published elsewhere [23,24]. The protocol, outcome measures and interview details are available from the EXPLORE website ( The study was approved by the institutional review boards at each of the participating institutions and participants provided written informed consent.

Study population

Study participants were recruited at each site from January 1999 to February 2001. Men were eligible if they were negative for HIV antibodies, 16 years or older, and reported having engaged in anal intercourse with one or more men in the past year. Men were excluded if they reported a mutually monogamous relationship for two or more years with a male partner known to be HIV seronegative. These behavioral eligibility criteria were established to specifically recruit a population of high-risk MSM for the intervention study using HIV incidence as the primary outcome of interest. Recruitment strategies included outreach in streets, at dance clubs, bars, bathhouses, sex clubs, health clubs and adult video stores. Advertising campaigns were conducted in each city, with emphasis in the gay media. Participants also came to the study through internet sites, community forums, community agencies, and referrals from other study participants and clinics.


As described previously [23,24], following informed consent, trained interviewers collected information on respondents’ demographics and history of sexually transmitted infections (STIs). Audio-computer-assisted self-interviewing (ACASI) technology was used to collect data on depressive symptoms, alcohol and drug use, and sexual behaviors. Participants were asked about sexual behaviors in the prior 6 months with partners of each HIV serostatus type (negative, positive, and unknown). The serostatus of a partner was based on participant's reports of what they believe to be the serostatus of a partner (e.g. a negative partner would be a partner who told the participant they were negative and the participant had no reason to doubt it). After completing the interviews, participants received HIV pre-test counseling and blood specimens were collected for HIV antibody testing.

Approximately 2 weeks after being screened, participants underwent post-test counseling to receive their HIV test result. Participants with a positive test result at the baseline were referred for medical and social services. Men who were negative for HIV antibodies at the baseline interview were asked to enroll in the trial.

Follow-up visits were scheduled every 6 months, up to 48 months, and consisted of behavioral surveys using both face-to-face interviews and the ACASI technology. All sexual behavior outcomes were collected by ACASI. To further mitigate against participants’ under-reporting of risk behaviors due to social desirability, no study staff had access to any ACASI risk behavior data for any participant, including during counseling sessions. Blood specimens were collected for testing for HIV antibodies.

Antibodies to HIV were detected by enzyme-linked immunosorbent assay. Sera shown to be reactive after a first test were retested in duplicate. Repeatedly reactive samples were confirmed through western blot assay or immunofluorescence assay. Participants with a positive test result at any follow-up visit were referred for medical and social services.

Statistical analysis

We conducted an observational analysis of data from a controlled trial. We adopted proportional hazards regression models of HIV seroconversion on the discrete time scale of twice-yearly visits. With this approach, the behavior variables were assessed at the same time that the blood was drawn for seroconversion testing, and refer to the previous 6-month time period. Additionally, since the behavioral variables were time-varying, the values of these covariates could change from one 6-month interval to the next.

To accommodate missing data, we applied the last-value-carried forward convention to the time-varying covariates except for indicators for the sexually transmitted diseases of chlamydia and gonorrhea. Although the randomized trial did not find a statistically significant effect on risk of HIV infection [24], all the analyses were stratified by study site and randomization arm.

Among covariates under consideration, depression was evaluated using a shortened version (seven items) of the Center for Epidemiologic Studies depression scale [25]. As a cut-off point has not been established for this shortened version, the score was divided in quartiles for analysis purposes with a higher score indicating more depressive symptoms. A primary partner was defined as someone who the participant has lived with or seen a lot, and to whom he felt a special commitment. Alcohol use in the previous 6 months was categorized as light (three or less drinks/day on no more than 1–2 days/week), moderate (four or five drinks/day on no more than 1–2 days/week, or one to five drinks/day on 3–6 days/week, or one to three drinks/day on a daily basis) or heavy (four or more drinks every day or six or more drinks on a typical day when drinking) [26,27]. Use of alcohol or drugs before sex was measured by the question ‘In the last 6 months, about how often did you get high or have a few drinks immediately before or during sex?’ with answer choices of never, occasionally, often, or all of the time. For the purposes of this analysis ‘never’ was coded as ‘no’ and the remaining categories were coded as ‘yes’. Drug use was evaluated by questions on drugs used in the previous 6 months, including marijuana, poppers, hallucinogens, sniffed cocaine, amphetamines, crack cocaine, smoked heroin or any injection drug use. Each drug was entered into the model. We also tested a model using two other drug variables: (1) number of different drugs used (categorized as: no drugs used, only one kind of drug, two different drugs or three or more different drugs); or (2) three drugs found to be associated with high-risk sexual risk behaviour [26]: amphetamine, nitrites or cocaine use, (categorized as: yes to any of them, no to all of them).

To identify predictors for HIV seroconversion, we first conducted univariate regression for each covariate. All covariates were then considered in a multivariate proportional hazards model and assessed using backward elimination with stay criteria set at P = 0.05. Note that an individual visit with missing data on any candidate covariate did not contribute to the model selection procedure. For this reason, we refined the estimation of the final model by considering only the predictors identified. We further examined the relationship between risk factors for HIV infection and sexual risk behaviors with single-predictor logistic regression models adjusting for randomization arm and visit. We employed the generalized estimating equations approach to account for the within-subject correlation of the repeated measures over time [28,29].

We adapted the approach of Kooperberg and Petitti [30] for logistic regression to obtain estimates for population attributable risk. It should be noted that population attributable risk estimates for individual predictors based on a multiplicative model may total more that 100%. Consequently, they are best interpreted as estimating the relative importance of various risk factors. All analyses were conducted using SAS Version 8.2 (SAS Institute Inc., Cary, North Carolina, USA).


Study population

The mean age of the 4295 enrolled participants was 34.0 years and 19.0% were 25 years of age or younger. Almost three-quarters (72.5%) of the men were white, 15.2% were Latino and 6.5% were African-American. Over one-third (35.8%) had less than a college degree. At baseline, the median number of partners was seven (25th percentile, three; 75 percentile, 18). About half of the men reported that they were in a primary relationship with a male sex partner. Of each of the three different partner serostatus types (negative, positive and unknown), the largest proportion of men reported having unknown status partners. Over two-thirds (69.1%) reported any unprotected anal intercourse, 48.0% reported unprotected receptive anal intercourse and 54.9% reported unprotected insertive anal intercourse. Unprotected oral sex with ejaculation was reported by 45.4% of the men. Heavy alcohol use, any non-injection drug use and injection drug use were reported by 11.0, 64.7 and 10.2% of men, respectively. At baseline, 72.1% of men reported using alcohol or drugs before having sex, 14.2% of men had scores in the highest two quartiles on the symptoms of depression scale and 15.4% of men reported having an STI in the prior 6 months.

Predictors of HIV acquisition

The overall HIV incidence in the study cohort was 2.1 per 100 person-years [95% confidence interval (CI), 1.9–2.4]. In univariate analysis of demographic variables, younger age, lower education and being Hispanic were associated with an increased risk of seroconversion (Table 1). With regard to male partners, in univariate analysis, men reporting having four or more male sex partners were more likely to become HIV infected in comparison with men who reported one or no partners. Men with an HIV-positive or unknown status primary partner or no primary partner were more likely to become HIV infected in comparison with men with an HIV-negative primary partner. Men who reported unprotected receptive anal intercourse with any serostatus partner were at increased risk of becoming HIV infected, as were men who reported unprotected insertive anal intercourse or unprotected oral sex with ejaculation with HIV-positive or unknown status partners. The use of non-injection drugs, drugs by injection, heavy alcohol and alcohol or drugs before sex were associated with an increase risk of HIV infection. Finally, self-reported sexually transmitted diseases and higher scores on the symptoms of depression scale were significantly associated with an increase risk of HIV infection.

Table 1
Table 1:
Risk factors for HIV seroconversion, The EXPLORE Study, 1999–2003.

In multivariate analysis, the only demographic variable which remained significantly associated with an increased risk of HIV infection was Black race/ethnicity (Table 1). With regard to sexual risk behaviors, men reporting four or more male sex partners, unprotected receptive anal intercourse with any serostatus partner and unprotected insertive anal intercourse with HIV-positive partners were at increased risk of HIV infection. Only one sexual risk variable, unprotected insertive anal intercourse with an HIV-negative partner, was significantly associated with a decreased risk of HIV infection. The substances remaining independently associated with an increased risk of HIV infection in multivariate analysis were amphetamines and heavy alcohol use, as was use of alcohol or drugs before sex. Only the second quartile on the symptoms of depression scale remained significantly associated with risk of HIV infection, as was self-reported occurrence of gonorrhea. We substituted the amphetamine use variable with two different measures of drug use (see Methods section) in the model. Neither of the variables was found to be significantly associated with HIV infection and did not change the estimates for the other covariates.

Based on studies reporting higher HIV prevalence among African-American MSM [31,32] but not higher levels of risk behaviour [31], we conducted exploratory bivariate analyses of Black race/ethnicity with the sexual risk behaviors which were significantly associated with an increased risk of HIV infection (four or more male partners, unprotected receptive anal intercourse with positive, negative or unknown status partners, unprotected insertive anal intercourse with positive partners). Black men were significantly less likely to report unprotected receptive anal intercourse with negative partners [hazard ratio (HR), 0.50; 95% CI, 0.40–0.62) and less likely to report four or more male partners (HR, 0.73; 95% CI, 0.60–0.88) in comparison with all other men. The percentage of Black men reporting any other sexual risk behavior was not significantly different from all other men (data not shown).

We also conducted an exploratory analysis to better understand the findings of an increased risk of HIV infection with unprotected receptive anal intercourse with an HIV-negative partner but a decreased risk with unprotected insertive anal intercourse with a negative partner. Men who reported unprotected insertive anal intercourse with a negative partner had a similar profile with regard to number of partners, primary partners and drug and alcohol use as men who reported unprotected receptive anal intercourse with a negative partner. However, men who reported unprotected receptive sex with an HIV-negative partner were significantly more likely to report the two highest sexual risk behaviors, unprotected receptive sex with an HIV-positive (P < 0.0001) or unknown status (P < 0.0001) partners in comparison with men who did not report unprotected receptive sex with an HIV-negative partner. In contrast, men who report unprotected insertive anal sex with an HIV-negative partner were not more likely to report these two high-risk sexual behaviors (unprotected receptive with positive: P = 0.41; with unknown status: P = 0.37) in comparison with men who did not report unprotected insertive anal sex with an HIV-negative partner.

Attributable risk analysis

Having four or more male sex partners accounted for the largest proportion of seroincidence (32.3%), followed by over one-quarter of seroincidence accounted for by alcohol or drug use before sex (29.0%) and by unprotected receptive anal intercourse with unknown status partners (28.4%) (Table 1). Just over one-fifth of seroincidence (21.6%) was accounted for by unprotected receptive anal intercourse with partners believed to be HIV negative and 18.3% of incidence was accounted for by unprotected receptive anal intercourse with positive partners. The use of amphetamines and self-reported symptoms of depression accounted for 16.3 and 11.1% of seroincidence, respectively. Although self-reported occurrence of gonorrhea had a relative hazard of over two, the attributable risk was only 4.3%, reflecting the low prevalence of gonorrhea.


Overall, the men enrolled in the EXPLORE cohort were at high risk of HIV infection, as indicated by their reported risk behaviors at baseline [23] and the observed HIV seroincidence of 2.1 per 100 person-years. It has been well-documented throughout the epidemic and confirmed in this study that among MSM, unprotected receptive anal intercourse, particularly with an HIV-positive partner, has highest risk for HIV seroconversion [12,14,15,33]. Of concern from a prevention perspective is the magnitude of risk associated with unprotected receptive anal intercourse with partners who were believed to be HIV negative. This level of risk could be explained by unrecognized infection by the partner, and those partners who were recently infected may have been highly infectious. A recent study of MSM in five US cities found that 48% of men found to HIV infected were unaware of their HIV infection [32]. This level of risk associated with HIV-negative partners could also be explained by a lack of communication about HIV serostatus, and thus presumptions about serostatus. In fact, analysis of the EXPLORE data at baseline indicated that poor communication skills with a partner about having safer sex were significantly associated with high-risk sexual behaviours [34]. Reports in the literature of the percentage of MSM who disclose their HIV infection status to sexual partners range widely from 23 to 57%, depending on HIV serostatus, perceived serostatus of the partner and relationship status of the partner [35–39].

At the same time, we found that men who reported unprotected insertive anal intercourse with an HIV-negative partner were at lower risk of HIV infection. Further examination of the data indicated that this group of men may engage in a different set of other sexual behaviors compared with men who have receptive intercourse. Given that mixtures of sexual behaviors differ among men, such results should be approached with caution with regard to prevention messages.

This study also found that the use of alcohol or drugs before sex and overall use of amphetamines and heavy alcohol were independent predictors of seroconversion. The use of amphetamines, particularly methamphetamine, has increased among MSM over the last few years, and in addition, alcohol use is highly prevalent among MSM [40]. The relationships between substance use, high-risk sexual behaviors and HIV infection are complex. Both amphetamine use and heavy alcohol use have been shown to be associated with high-risk sexual behaviours [27,40–45], as was observed in exploratory analysis in this study (data not shown). Several studies have demonstrated an independent association of amphetamine use and heavy alcohol use and risk of HIV infection [8,14,46,47]. In the EXPLORE Study, the independent association of these substance use-related variables with HIV infection could be explained by several factors. First, those using substances could be those who had a higher frequency of unprotected intercourse or higher condom failure rates. For example, Stone et al. [48] reported an increase in condom failure (slippage and breakage) rates among MSM using amphetamines or heavy alcohol. Risk behaviors may also have been under-reported among participants who used substances. There also may have been some physiological effects of some substances, such as amphetamines, which could facilitate acquisition of HIV, including prolongation of sex or trauma to the anus or rectum. Finally, there also is evidence that amphetamines may interfere with adherence to antiretroviral treatment or the effectiveness of antiretroviral treatment [49,50]. Thus, if amphetamine-using EXPLORE participants chose HIV-infected partners who were also using amphetamines, these partners may have been highly infectious due to a reduction in the effectiveness of their antiretroviral treatment.

The only self-reported STI found to be independently associated with risk of HIV infection in the EXPLORE cohort was occurrence of gonorrhea. During follow-up, 1.4 to 2.3% of men reported having gonorrhea during any one 6-month period. Evidence is limited about the role of gonorrhea, as opposed to ulcerative STIs, in the acquisition of HIV among MSM. In multivariate analysis, some studies found that gonorrhea was associated with increased risk of HIV seroconversion [9,13,51], but another study did not [16,52]. This increase in risk associated with a non-ulcerative STI could be a result of disruption of mucous membranes due to local inflammation or activation and recruitment of CD4 cells at the mucosal surface.

As observed in other studies, Black men were at increased risk of HIV infection [31,32] and at the same time, were less or no more likely to report HIV sexual risk behaviours [31]. It may be that levels of social desirability about reporting risk behaviors differ by race/ethnicity, even with the use of ACASI technology. There are other factors, not measured in this study, which may explain differences in HIV incidence by race/ethnicity, including the prevalence of genetic polymorphisms for HIV susceptibility [53] or prevalence of STIs [54,55] as well as behavioral factors such as partner selection within high prevalence networks. Exploration of other factors, perhaps through qualitative ethnographic techniques, may provide more comprehensive information for planning critically needed prevention strategies.

The preponderance of studies has not shown an association between depression and high-risk sexual behaviour [56–62] or with HIV infection [47]. In this study, the association between HIV infection and the highest scores of depressive symptoms did not remain significant once controlling for other risk factors. It is unclear why men with some symptoms were found to be at higher risk. These men may be the least likely to be receiving services for their symptoms. As with substance use, depressive symptoms in this group may be a marker for an increase in risk behaviors due to unmeasured factors or an increased in frequency of unprotected intercourse.

The men in the EXPLORE cohort are not necessarily representative of MSM in the six cities. The eligibility criteria were established to enroll a high-risk study sample for a trial with an HIV infection endpoint. Furthermore, generalizability is limited since Black and Latino men, younger men and those of lower socio-economic status were less likely to enroll in the study, were more likely to not be eligible due to behavioral risk and were more likely to be HIV-infected at screening [23].

The attributable risk analysis indicates which factors could have largest impact on reducing the occurrence of new HIV infections among MSM. Of most importance is the reduction in the number of sexual partners, a factor which accounted for 32% of the incident infections, as well as reduction in alcohol and drug use in combination with sex and overall amphetamine use. However, interventions must address the evidence that a ‘syndemic’ of multiple health and mental health issues – HIV risk behaviors, substance use and depressive symptoms – is occurring among MSM [56]. MSM affected by this syndemic may not be receiving the services they need and current HIV prevention programs need to be adapted or changed to focus on substance use and abuse and other mental health issues, along with HIV risk reduction, in order have an impact within various subpopulations.


We gratefully acknowledge the contributions of the study participants.

Sponsorship: This work was supported by the HIV Network for Prevention Trials and sponsored by the US National Institute of Allergy and Infectious Diseases and the National Institute on Alcohol Abuse and Alcoholism, of the National Institutes of Health, Department of Health and Human Services, through contract N01 AI35176 with Abt Associates Inc; contract N01 AI45200 with the Fred Hutchinson Cancer Research Center; and subcontracts with the Denver Public Health, the Fenway Community Health Center, the Howard Brown Health Center, the New York Blood Center, the Public Health Foundation Inc., and the University of Washington. In addition, this work was supported by the HIV Prevention Trials Network and sponsored by the National Institute of Allergy and Infectious Diseases, the National Institute of Child Health and Human Development, the National Institute on Drug Abuse, the National Institute of Mental Health, and the Office of AIDS Research, of the National Institutes of Health, US Dept of Health and Human Services, through a co-operative agreement with Family Health International (co-operative agreement 5 U01 AI46749) with a subsequent subcontract to Abt Associates Inc. with subcontracts to the Howard Brown Health Center and Denver Public Health; co-operative agreement U01 AI48040 to the Fenway Community Health Center, co-operative agreement U01 AI48016 to Columbia University (including a subagreement with the New York Blood Center); and co-operative agreement U01 AI47981 to the University of Washington; and co-operative agreement U01 AI47995 to the University of California, San Francisco.


1. Centers for Disease Control and Prevention (CDC). HIV/AIDS Surveillance Report 2002. Atlanta, Georgia: CDC; 2002. 14:10.
2. van Griensven GJ, Hessol NA, Koblin BA, Byers RH, O'Malley PM, Albercht-van Lent N, et al. Epidemiology of human immunodeficiency virus type 1 Infection among homosexual men participating in hepatitis B vaccine trials in Amsterdam, New York City, and San Francisco, 1978–1990. Am J Epidemiol 1993; 137:909–915.
3. Vu MQ, Steketee RW, Valleroy L, Weinstock H, Karon J, Janssen R. HIV incidence in the United States, 1978–1999. J Acquir Immune Defic Syndr 2002; 31:188–201.
4. Schechter MT, Boyko WJ, Douglas B, Willoughby B, McLeod A, Maynard M, et al. The Vancouver Lymphadenopathy-AIDS Study: 6. HIV seroconversion in a cohort of homosexual men. Can Med Assoc J 1986; 135:1355–1360.
5. Chmiel JS, Detels R, Kaslow RA, Van Raden M, Kingsley LA, Brookmeyer R. Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study. Am J Epidemiol 1987; 126:568–577.
6. van Griensven GJ, Tielman RA, Goudsmit J, van der NJ, de Wolf F, de Vroome EM, et al. Risk factors and prevalence of HIV antibodies in homosexual men in the Netherlands. Am J Epidemiol 1987; 125:1048–1057.
7. Coates RA, Calzavara LM, Read SE, Fanning MM, Shepherd FA, Klein MH, et al. Risk factors for HIV infection in male sexual contacts of men with AIDS or an AIDS-related condition. Am J Epidemiol 1988; 128:729–739.
8. Burcham JL, Tindall B, Marmor M, Cooper DA, Berry G, Penny R. Incidence and risk factors for human immunodeficiency virus seroconversion in a cohort of Sydney homosexual men. Med J Aust 1989; 150:634–639.
9. Seage GR III, Mayer KH, Horsburgh CR Jr, Holmberg SD, Moon MW, Lamb GA. The relation between nitrite inhalants, unprotected receptive anal intercourse, and the risk of human immunodeficiency virus infection. Am J Epidemiol 1992; 135:1–11.
10. Samuel MC, Hessol N, Shiboski S, Engel RR, Speed TP, Winkelstein W Jr. Factors associated with human immunodeficiency virus seroconversion in homosexual men in three San Francisco cohort studies, 1984–1989. J Acquir Immune Defic Syndr 1993; 6:303–312.
11. Ostrow DG, DiFranceisco WJ, Chmiel JS, Wagstaff DA, Wesch J. A case-control study of human immunodeficiency virus type 1 seroconversion and risk-related behaviors in the Chicago MACS/CCS Cohort, 1984–1992. Multicenter AIDS Cohort Study. Coping and Change Study. Am J Epidemiol 1995; 142:875–883.
12. Koblin BA, Taylor PE, Avrett S, Stevens CE. The feasibility of HIV-1 vaccine efficacy trials among gay/bisexual men in New York City: Project ACHIEVE. AIDS Community Health Initiative Enroute to the Vaccine EFfort. AIDS 1996; 10:1555–1561.
13. Buchbinder SP, Douglas JM Jr, McKirnan DJ, Judson FN, Katz MH, MacQueen KM. Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate. J Infect Dis 1996; 174:954–961.
14. Page-Shafer K, Veugelers PJ, Moss AR, Strathdee S, Kaldor JM, van Griensven GJ. Sexual risk behavior and risk factors for HIV-1 seroconversion in homosexual men participating in the Tricontinental Seroconverter Study, 1982–1994. Am J Epidemiol 1997; 146:531–542.
15. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999; 150:306–311.
16. Darrow WW, Echenberg DF, Jaffe HW, O'Malley PM, Byers RH, Getchell JP, et al. Risk factors for human immunodeficiency virus (HIV) infections in homosexual men. Am J Public Health 1987; 77:479–483.
17. Renzi C, Douglas JM Jr, Foster M, Critchlow CW, Ashley-Morrow R, Buchbinder SP, et al. Herpes simplex virus type 2 infection as a risk factor for human immunodeficiency virus acquisition in men who have sex with men. J Infect Dis 2003; 187:19–25.
18. Buchbinder SP, Vittinghoff E, Heagerty PJ, Celum CL, Seage GR III, Judson FN, et al. Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr 2005; 39:82–89.
19. Kuiken CL, van Griensven GJ, de Vroome EM, Coutinho RA. Risk factors and changes in sexual behavior in male homosexuals who seroconverted for human immunodeficiency virus antibodies. Am J Epidemiol 1990; 132:523–530.
20. Katz MH, Schwarcz SK, Kellogg TA, Klausner JD, Dilley JW, Gibson S, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health 2002; 92:388–394.
21. Scheer S, Chu PL, Klausner JD, Katz MH, Schwarcz SK. Effect of highly active antiretroviral therapy on diagnoses of sexually transmitted diseases in people with AIDS. Lancet 2001; 357:432–435.
22. Chen SY, Gibson S, Katz MH, Klausner JD, Dilley JW, Schwarcz SK, et al. Continuing increases in sexual risk behavior and sexually transmitted diseases among men who have sex with men: San Francisco, Calif, 1999–2001, USA. Am J Public Health 2002; 92:1387–1388.
23. Koblin BA, Chesney MA, Husnik MJ, Bozeman S, Celum CL, Buchbinder S, et al. High-risk behaviors among men who have sex with men in 6 US cities: baseline data from the EXPLORE Study. Am J Public Health 2003; 93:926–932.
24. The EXPLORE Study Team. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study.Lancet 2004; 364:41–50.
25. Mirowsky J, Ross CE. Age and depression. J Health Soc Behav 1992; 33:187–205.
26. Colfax G, Vittinghoff E, Husnik MJ, McKirnan D, Buchbinder S, Koblin B, et al. Substance use and sexual risk: a participant- and episode-level analysis among a cohort of men who have sex with men. Am J Epidemiol 2004; 159:1002–1012.
27. Woody GE, Donnell D, Seage GR, Metzger D, Marmor M, Koblin BA, et al. Non-injection substance use correlates with risky sex among men having sex with men: data from HIVNET. Drug Alcohol Depend 1999; 53:197–205.
28. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73:13–22.
29. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42:121–130.
30. Kooperberg C, Petitti DB. Using logistic regression to estimate the adjusted attributable risk of low birthweight in an unmatched case-control study. Epidemiology 1991; 2:363–366.
31. Torian LT, Koblin BA, Guilin V, Ren L, Makki HA, MacKellar DA, et al. High HIV seroprevalence and wide race differentials in young men who have sex with men sampled at public venues in New Yorkity, 1998–1999.Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 2001. [abstract 212]
32. Anon. HIV prevalence, unrecognized infection, and HIV testing among men who have sex with men – five U.S. cities, June 2004–April 2005.MMWR Morb Mortal Wkly Rep 2005; 52:597–601.
33. Stevens CE, Taylor PE, Zang EA, Morrison JM, Harley EJ, Rodriguez dC, et al. Human T-cell lymphotropic virus type III infection in a cohort of homosexual men in New York City. JAMA 1986; 255:2167–2172.
34. Chesney MA, Koblin BA, Barresi PJ, Husnik MJ, Celum CL, Colfax G, et al. An individually tailored intervention for HIV prevention: baseline data from the EXPLORE Study. Am J Public Health 2003; 93:933–938.
35. Ciccarone DH, Kanouse DE, Collins RL, Miu A, Chen JL, Morton SC, et al. Sex without disclosure of positive HIV serostatus in a US probability sample of persons receiving medical care for HIV infection. Am J Public Health 2003; 93:949–954.
36. De Rosa CJ, Marks G. Preventive counseling of HIV-positive men and self-disclosure of serostatus to sex partners: new opportunities for prevention. Health Psychol 1998; 17:224–231.
37. Crepaz N, Marks G. Serostatus disclosure, sexual communication and safer sex in HIV-positive men. AIDS Care 2003; 15:379–387.
38. Prestage G, Van DV, Grulich A, Kippax S, McInnes D, Hendry O. Gay men's casual sex encounters: discussing HIV and using condoms. AIDS Care 2001; 13:277–284.
39. Wolitski RJ, Rietmeijer CA, Goldbaum GM, Wilson RM. HIV serostatus disclosure among gay and bisexual men in four American cities: general patterns and relation to sexual practices. AIDS Care 1998; 10:599–610.
40. Halkitis PN, Parsons JT, Stirratt MJ. A double epidemic: crystal methamphetamine drug use in relation to HIV transmission among gay men. J Homosex 2001; 41:17–35.
41. Shoptaw S, Reback CJ, Freese TE. Patient characteristics, HIV serostatus, and risk behaviors among gay and bisexual males seeking treatment for methamphetamine abuse and dependence in Los Angeles. J Addict Dis 2002; 21:91–105.
42. Colfax GN, Mansergh G, Guzman R, Vittinghoff E, Marks G, Rader M, et al. Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: a venue-based comparison. J Acquir Immune Defic Syndr 2001; 28:373–379.
43. Molitor F, Truax SR, Ruiz JD, Sun RK. Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. West J Med 1998; 168:93–97.
44. Seage GR III, Mayer KH, Wold C, Lenderking WR, Goldstein R, Cai B, et al. The social context of drinking, drug use, and unsafe sex in the Boston Young Men Study. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:368–375.
45. Stall R, Paul JP, Greenwood G, Pollack LM, Bein E, Crosby GM, et al. Alcohol use, drug use and alcohol-related problems among men who have sex with men: the Urban Men's Health Study. Addiction 2001; 96:1589–1601.
46. Chesney MA, Barrett DC, Stall R. Histories of substance use and risk behavior: precursors to HIV seroconversion in homosexual men. Am J Public Health 1998; 88:113–116.
47. Penkower L, Dew MA, Kingsley L, Becker JT, Satz P, Schaerf FW, et al. Behavioral, health and psychosocial factors and risk for HIV infection among sexually active homosexual men: the Multicenter AIDS Cohort Study. Am J Public Health 1991; 81:194–196.
48. Stone E, Heagerty P, Vittinghoff E, Douglas JM Jr, Koblin BA, Mayer KH, et al. Correlates of condom failure in a sexually active cohort of men who have sex with men. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:495–501.
49. Ellis RJ, Childers ME, Cherner M, Lazzaretto D, Letendre S, Grant I. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis 2003; 188:1820–1826.
50. Reback CJ, Larkins S, Shoptaw S. Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care 2003; 15:775–785.
51. Craib KJ, Meddings DR, Strathdee SA, Hogg RS, Montaner JS, O'Shaughnessy MV, et al. Rectal gonorrhoea as an independent risk factor for HIV infection in a cohort of homosexual men. Genitourin Med 1995; 71:150–154.
52. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75:3–17.
53. Marmor M, Sheppard HW, Donnell D, Bozeman S, Celum C, Buchbinder S, et al. Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr 2001; 27:472–481.
54. Miller WC, Zenilman JM. Epidemiology of chlamydial infection, gonorrhea, and trichomoniasis in the United States –2005. Infect Dis Clin North Am 2005; 19:281–296.
55. Laumann EO, Youm Y. Racial/ethnic group differences in the prevalence of sexually transmitted diseases in the United States: a network explanation. Sex Transm Dis 1999; 26:250–261.
56. Stall R, Mills TC, Williamson J, Hart T, Greenwood G, Paul J, et al. Association of co-occurring psychosocial health problems and increased vulnerability to HIV/AIDS among urban men who have sex with men. Am J Public Health 2003; 93:939–942.
57. Mills TC, Paul J, Stall R, Pollack L, Canchola J, Chang YJ, et al. Distress and depression in men who have sex with men: the Urban Men's Health Study. Am J Psychiatry 2004; 161:278–285.
58. Beck A, McNally I, Petrak J. Psychosocial predictors of HIV/STI risk behaviours in a sample of homosexual men. Sex Transm Infect 2003; 79:142–146.
59. Perdue T, Hagan H, Thiede H, Valleroy L. Depression and HIV risk behavior among Seattle-area injection drug users and young men who have sex with men. AIDS Educ Prev 2003; 15:81–92.
60. Strathdee SA, Hogg RS, Martindale SL, Cornelisse PG, Craib KJ, Montaner JS, et al. Determinants of sexual risk-taking among young HIV-negative gay and bisexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:61–66.
61. Crepaz N, Marks G. Are negative affective states associated with HIV sexual risk behaviors? A meta-analytic review. Health Psychol 2001; 20:291–299.
62. Dilley JW, McFarland W, Sullivan P, Discepola M. Psychosocial correlates of unprotected anal sex in a cohort of gay men attending an HIV-negative support group. AIDS Educ Prev 1998; 10:317–326.


The EXPLORE Study Team

For each group/site the data is presented as site principal investigator, followed by names of staff, listed in alphabetic order.

Protocol co-chairs: Beryl Koblin, Margaret Chesney and Thomas Coates

Boston's Fenway Community Health Center and the Latin American Health Institute: Kenneth Mayer (site principal investigator), Felipe Agredano, Eduardo Aguilu, Rodrigo Barahona, Keith Bell, Christine Borges, Manual Burnias, Mark Cayabayab, Dan Church, Allison Cohn, Yvonne Colon, Janet Dargon, Nancy DeSousa, Judy Erdman, Josh Gagne, Eliza Goodhue, Juan Jimenez, William Johnson, Robert Knauz, Wilfred Labiosa, Ana Lara, Darren LeBlanc, Vin Longo, Marc Manseau, Marshall Miller, Matthew Mimiaga, Elie Mohns, Arnel Montenegro, David Pantalone, Oscar Patino, Tracey Rogers, Edual Ruiz, Steve Safren, Liz Salomon, Julio Silva, Laura van der Leeden, Rodney VanDerwarker, and Curt Weber.

Chicago's Howard Brown Community Health Center: David McKirnan (site principal investigator), Althea Batticks, Jason Bird, Liz Bradshaw, Robert Brown, Tom Buckingham, Toni Buckingham, Kelly Carson, Irene Chubinsky, Scott Clark, Scott Cook, Jeff Eichholz, Erica Gaffold, Sanford Gaylord, Mark Hartfield, David Henry, Brent Hope, Dale Gluth, Shane Gosselink, Jenny Hopwood, Laura Hosto, Jennifer Howard, D. J. Jacques, Heather Jandura, Susan Killelea, Andy Knight, Simone Koehlinger, Melissa Kohnke, Felicity LaBoy, Han Lee, Kandis Martin, Nicole Martin, Michele McGrady, Cheron McNeal, Denise Miles, Gino Moore, Michael Munn, Jose Narvaez, Aisha Nawab, Arlette Oblaza, Kevin O'Keefe, Liz Perez, Elisse Pertiller, Kelly Picketts, Borris Powell, Chris Powers, Bart Ramey, Ingrid Rodriguez, Laurez Rutledge, Porfirio Sanchez, Michael Saven, Chris Schmidt, Mark Schulze, Jim Skinner, David Snyder, Al Sorrese, Justin St. Andre, Gerry Taranzo, Ted Taylor, Sonia Torres, Kristin Vanfossan, Gregory Victorianne, and Erik Wetz.

Denver Public Health: Franklyn Judson (site principal investigator), Misty Aas, Ramon Armendariz, Chloe Bailey, Brian Bost, Julie Caine, David Cline, Stuart Cooper, Kent Curtis, Beth Deyo, John Douglas, Michael Furhman, Rene Gonzalez, Jeff Hiller, Paul Huber, Sharon Huber, Ken Miller, Philip Osteen, Laurie Peter, Doug Robinson, Dave Ward, Tim Wright, and Andrew Yale.

New York Blood Center: Beryl Koblin (site principal investigator), Anne Aldrich, Louise Austin, Lynne Bartell, Jane Bensel, Roberta Bernet, Damian Bird, Adam Bonilla, Carolyn Booher, Michael Camacho, Bradley Clark, Kent Curtis, Nikki Englert, Tonya Flores, George Gates, Corinne Geller, Octavio Gonzalez, Denise Goodman, Krista Goodman, Joshua Hinson, Sean Lawrence, Thomas Lee, Jay Loeffel, Angelo Luna, Larry Metzger, Carolle Morris, Patrick O'Quinn, Eric Ortiz, Ofiji Parris, Alfredo Perez, Terrence Precord, Alberto Rodriguez, Jason Santiago, Craig Siulinski, Leah Strock, Paul Teixeira, Eric Torres, Francesca Valenti, Curt Weber, Avery White, and Jess Zimmerman.

San Francisco Department of Public Health: Susan Buchbinder (site principal investigator), Grant Colfax (site co-principal investigator), Jonas Abella, Mike Ahern, Ari Bacharat, Alba Barreto, Christopher Boyden-DeShazer, Jesse Brooks, Meredith Broome, Tony Buckman, David Colbert, Emily Cole, Alfonso Diaz, Michael Edgar, Beth Faraguna, Paige Fratesi, Vincent Fuqua, Reggie Gage, Anjali Garg, Dale Gluth, Ted Guggenheim, Gavin Hall, Thomas Knoble, Rachel Langdon, Irene Lee, Jennifer Lessard, Nicole Lightburn, Tim Matheson, Corvette Moore, Mario Moreno, Paul O'Malley, Jennifer Owen, Jesus Perez, Robin Rifkin, Chris Rubino, Mateo Rutherford, Jennifer Sarche, Georgia Schreiber, Rob Schwarz, Craig Siulinski, John Stryker, Jason Tomasian, Jim Touchstone, Seth Watkins, Sarah Wheeler, Belinda Van, and Allison Zerbe.

Seattle's University of Washington: Connie Celum (site principal investigator), Scott Britt, Fransing Daisy, Aline Dang, Tennessee Dickenson, Niles Eaton, Terry Elliott, Raymond Evans, Paul Farley, Mark Fleming, George Froehle, Jerome Galea, Hal Garcia-Smith, Patrick Gonzalez, Bruce Gooding, Krista Goodman, Justin Haines, Keifa Herzog, Rick Hieb, Eric Hildebrandt, Damon Jameson, E. J. Janson, Thom Kelty, Bill Krutch, Erin Lennon, Matt Leidholm, Alfredo Lopez, Paul Louey, Matt Meko, Jenny Melmed, Dany-Paul Mucha, Shelley Ozscuro, Joe Picciano, Jim Price, Monica Rayne, Alex Rodriguez, Barbara Steele, Nancy Stoaks, Jason Stucky, Matthew Swank, Stephen Tabet, Jeff Thompson, Dennis I. Torres, John Torres, Patrick Tschumper, Paul B. Verano, Ken Wheeler, and Robert Yoon.

Abt Associates, Inc.: Dana Benet, Sam Bozeman, Sam Clark, Anne Coletti, Michelle Culp, Kirsten Firla, Michael Iatesta, Maria Madison, Sean McKee, and George Seage.

Center for AIDS Prevention Studies: Margaret Chesney and Thomas Coates (principal investigators), Patrick Barresi, Kevin Filocamo, Cliff Leonardi, Scott Stumbo, and Matthew Troy.

Statistical Center for HIV/AIDS Research and Prevention: Neil Albright, Geetha Beauchamp, Rana Bonnice, Lynette Browne, Claire Chapdu, Maya Covarrubias, Martina Deseyve, Lynda Emel, Alice Fisher, Eileen Hess, Sarah Holte, Yijian Huang, Marla Husnik, MaryAnn Klotz, Craig Magaret, Wolfe Maykut, Peter McDonnell, Barbara Metch, Geoff Minerbo, Lisa Ondrejcek, Jennifer Schille, Steve Self, and Al Williams.

Central Laboratory: Karen Anderson, Rhonda Canotal, Yao Tsing Chow, Naana Cleland, Dale Dondero, Barryett Enge, Eileen Liu, Chip Sheppard, Brent Sugimoto, Sean Watson.


alcohol use; depression; HIV; men who have sex with men; sexually transmitted diseases; substance use

© 2006 Lippincott Williams & Wilkins, Inc.